Associations - EGFR amplification

EGFR amplification EGFR amplification	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: B - Late Trials
EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: B - Late Trials
EGFR amplification EGFR amplification	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C2 – Inclusion Criteria
EGFR amplification EGFR amplification	Glioblastoma GBM	ABT-414 Sensitive: C2 – Inclusion Criteria
EGFR amplification EGFR amplification	Glioblastoma GBM	lapatinib Sensitive: C2 – Inclusion Criteria
EGFR amplification EGFR amplification	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	afatinib Sensitive: C2 – Inclusion Criteria
EGFR amplification EGFR amplification	Lung Cancer Lung Cancer	gefitinib Resistant: C2 – Inclusion Criteria
EGFR amplification EGFR amplification	Glioblastoma GBM	KD019 Sensitive: C2 – Inclusion Criteria
EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	Immunotherapy Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Gastric Cancer Gastric Cancer	cetuximab Sensitive: C3 – Early Trials
EGFR amplification EGFR amplification	Glioblastoma GBM	erlotinib Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Melanoma Melanoma	Immunotherapy Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Colorectal Cancer CRC	panitumumab Sensitive: C3 – Early Trials
EGFR amplification EGFR amplification	Non Small Cell Lung Cancer NSCLC	osimertinib Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Solid Tumor Solid Tumor	ABSK-091 Sensitive: C3 – Early Trials
EGFR amplification EGFR amplification	Lung Cancer Lung Cancer	icotinib Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Non Small Cell Lung Cancer NSCLC	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR amplification EGFR amplification	Non Small Cell Lung Cancer NSCLC	bevacizumab + gefitinib Sensitive: C3 – Early Trials
EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + afatinib Sensitive: C3 – Early Trials
EGFR amplification EGFR amplification	Lung Adenocarcinoma LUAD	afatinib Sensitive: C4 – Case Studies
EGFR amplification EGFR amplification	Glioblastoma GBM	verteporfin Sensitive: D – Preclinical
EGFR amplification EGFR amplification	Glioma Glioma	talazoparib Sensitive: D – Preclinical